1. Economics of Treatments for Non-Small Cell Lung Cancer
- Author
-
Christos Chouaid, Alain Vergnenegre, Kukovi Atsou, Gilles Hejblum, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Pathologie respiratoire et allergologie [CHU Limoges], CHU Limoges, C Chouaid, K Atsou, G Hejblum, SCHILLER A, Pôle de Pharmacie - Santé Publique - Information médicale [Saint-Antoine], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC)
- Subjects
Oncology ,MESH: Combined Modality Therapy ,Lung Neoplasms ,Cost effectiveness ,Cost-Benefit Analysis ,MESH: Taxoids ,Docetaxel ,0302 clinical medicine ,Glutamates ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,030212 general & internal medicine ,health care economics and organizations ,Health Policy ,Combined Modality Therapy ,3. Good health ,MESH: Antineoplastic Combined Chemotherapy Protocols ,MESH: Quinazolines ,Pemetrexed ,030220 oncology & carcinogenesis ,Taxoids ,Erlotinib ,medicine.drug ,medicine.medical_specialty ,Guanine ,Erlotinib Hydrochloride ,03 medical and health sciences ,MESH: Glutamates ,Internal medicine ,Humans ,Lung cancer ,MESH: Guanine ,Pharmacology ,MESH: Humans ,Performance status ,business.industry ,Public Health, Environmental and Occupational Health ,Cancer ,medicine.disease ,MESH: Lung Neoplasms ,respiratory tract diseases ,Surgery ,Localized disease ,Quinazolines ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,MESH: Carcinoma, Non-Small-Cell Lung ,MESH: Cost-Benefit Analysis - Abstract
International audience; The purpose of this article is to review the economics of treatments for non-small cell lung cancer (NSCLC). We systematically analysed the cost effectiveness of treatments for the different stages of NSCLC, with particular emphasis on more recently approved agents. Numerous economic analyses in NSCLC have been conducted, with a variety of methods and in a number of countries. In patients with localized disease, adjuvant chemotherapy appears to have greater cost effectiveness than observation; however, there are few published data. In locally advanced disease, combined modalities (chemotherapy, surgery and/or radiotherapy) are probably cost effective, but high-quality economic analyses are lacking. In advanced NSCLC, third-generation chemotherapies used in the first-line setting can be administered with acceptable incremental cost effectiveness. In the second-line setting, new agents (docetaxel, pemetrexed and erlotinib) have acceptable cost effectiveness. The lack of cost-utility analyses for elderly patients and patients with a poor prognosis rules out firm conclusions. This review suggests that most therapies for NSCLC are cost effective when the patient has a good performance status, with an incremental cost-effectiveness ratio under USD 50,000 per life-year gained in the majority of cases.
- Published
- 2009